Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 607-613

  Apostolou, F ^a   Gazi, I F ^a   Lagos, K ^a   Tellis, C C ^b   Tselepis, A D ^b   Liberopoulos, E N ^a   Elisaf, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cytokines; Epstein Barr virus; Lipids; Lipoprotein associated phospholipase A2 (Lp PLA2); Small dense LDL particles

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOKINE; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INFECTIOUS MONONUCLEOSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHILD; CHOLESTEROL ESTER TRANSFER PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FEVER; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEINS; MALE;

EID: 77957705454     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.006     Document Type: Article

References (42)

1. O'Connor S., Taylor C., Campbell L.A., Epstein S., Libby P. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 2001, 7:780-788.
2. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
3. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
4. Koenig W., Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009, 23:85-92.
5. Memon R.A., Fuller J., Moser A.H., Feingold K.R., Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol 1999, 277:R94-103.
6. Trimoreau F., Francois B., Desachy A., et al. Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome. Mediat Inflamm 2000, 9:197-200.
7. Khovidhunkit W., Memon R.A., Shigenaga J.K., et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999, 48:1524-1531.
8. Mackness M.I., Mackness B., Durrington P.N. Paraoxonase and coronary heart disease. Atherosclerosis 2002, 3:49-55.
9. Cabana V.G., Reardon C.A., Feng N., et al. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 2003, 44:780-792.
10. Apostolou F., Gazi I.F., Kostoula A., et al. Persistence of an atherogenic lipid profile after treatment of acute infection with brucella. J Lipid Res 2009, 50:2532-2539.
11. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007, 7:53-72.
12. Badiou S., Merle De Boever C., Dupuy A.M., et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?. Atherosclerosis 2003, 168:107-113.
13. Rufail M.L., Schenkein H.A., Barbour S.E., Tew J.G., van Antwerpen R. Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis. J Lipid Res 2005, 46:2752-2760.
14. Macsween K.F., Crawford D.H. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003, 3:131-140.
15. Tselepis A.D., Dentan C., Karabina S.A., Chapman M.J., Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995, 15:1764-1773.
16. Liberopoulos E.N., Papavasiliou E., Miltiadous G.A., et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int 2004, 24:580-589.
17. Gazi I., Lourida E.S., Filippatos T., et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
18. Kusuoka H., Hoffman J.I. Advice on statistical analysis for circulation research. Circ Res 2002, 91:662-671.
19. Espinola-Klein C., Rupprecht H.J., Blankenberg S., et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002, 33:2581-2586.
20. Espinola-Klein C., Rupprecht H.J., Blankenberg S., et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002, 105:15-21.
21. Khairy P., Rinfret S., Tardif J.C., et al. Absence of association between infectious agents and endothelial function in healthy young men. Circulation 2003, 107:1966-1971.
22. van Leeuwen H.J., Heezius E.C., Dallinga G.M., et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003, 31:1359-1366.
23. Fraunberger P., Hahn J., Holler E., Walli A.K., Seidel D. Serum cholesterol levels in neutropenic patients with fever. Clin Chem Lab Med 2002, 40:304-307.
24. Grunfeld C., Pang M., Doerrler W., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
25. Gierens H., Nauck M., Roth M., et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000, 20:1777-1783.
26. Feingold K.R., Hardardottir I., Grunfeld C. Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss 1998, 37(suppl. 1):66-74.
27. Ribalta J., Vallve J.C., Girona J., Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003, 6:177-187.
28. Mooser V., Berger M.M., Tappy L., et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol 2000, 20:1137-1142.
29. Milionis H.J., Winder A.F., Mikhailidis D.P. Lipoprotein (a) and stroke. J Clin Pathol 2000, 53:487-496.
30. Ramharack R., Barkalow D., Spahr M.A. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998, 18:984-990.
31. Gazi I., Tsimihodimos V., Filippatos T., et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006, 55:885-891.
32. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
33. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139:307-315.
34. Van Lenten B.J., Wagner A.C., Nayak D.P., et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 103:2283-2288.
35. Jin W., Sun G.S., Marchadier D., et al. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ Res 2003, 92:644-650.
36. Ly H., Francone O.L., Fielding C.J., et al. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res 1995, 36:1254-1263.
37. van Leeuwen H.J., van Beek A.P., Dallinga-Thie G.M., et al. The role of high density lipoprotein in sepsis. Neth J Med 2001, 59:102-110.
38. McQueen M.J., Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
39. Tsimihodimos V., Gazi I., Kostara C., Tselepis A.D., Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 2007, 42:403-409.
40. Kilic S.S., Aydin S., Kilic N., et al. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005, 11:7351-7354.
41. Parra S., Alonso-Villaverde C., Coll B., et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007, 194:175-181.
42. Aslan M., Nazligul Y., Horoz M., et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008, 196:270-274.